Open access
Sep 2026
Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis
Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).
H. Mian, M. Faisal, Tie-Ning Chen et al.
· Cancer · 0 citations